Real-world study of tenofovir amibufenamide in the treatment of patients with hepatitis B cirrhosis
10.3760/cma.j.cn501113-20240905-00478
- VernacularTitle:艾米替诺福韦治疗乙型肝炎肝硬化患者的真实世界研究
- Author:
Ying HAN
1
;
Ajuan ZENG
1
;
Xueying LIANG
1
;
Yanna LIU
1
;
Keke JIN
1
;
Huiguo DING
1
Author Information
1. 首都医科大学附属北京佑安医院肝病消化中心二科，北京 100069
- Publication Type:Journal Article
- Keywords:
Hepatitis B;
Tenofovir amibufenamide;
Cirrhosis;
Hepatitis B;
Antiviral treatment;
Therapy
- From:
Chinese Journal of Hepatology
2024;32(S1):30-34
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the short-term antiviral efficacy and safety profile of tenofovir amibufenamide (TMF) in patients with hepatitis B cirrhosis.Methods:The biochemical indexes, renal function, and complication status in patients with hepatitis B cirrhosis who were treated with tenofovir amibufenamide (TMF) in Beijing You'an Hospital Affiliated to Capital Medical University from March 2022 to June 2024 were retrospectively analyzed.Results:A total of 98 cases with hepatitis B cirrhosis were included. Among them, 62 and 36 cases with hepatitis B cirrhosis had previously undergone partial resection for hepatocellular carcinoma. 66.7% (62/93) of the treated patients were HBV DNA negative before treatment. The longest follow-up time for medication was 24 months, with an average follow-up of (14.1±4.7) months. There were no statistically significant differences in aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin (TBil) levels at 18 months of treatment compared with those before treatment ( P>0.05). The ALT return to normal rate was 91.3%. The HBV DNA negativity rate was 90.6% and 93.5% at 18 and 12 months of follow-up, respectively. There were no significant changes in the estimated glomerular filtration rate (eGFR) and low-density lipoprotein cholesterol (LDL-C) compared with those before treatment ( P>0.05). 36 cases were still HBV DNA positive (including 31 treated and 5 never treated) before treatment. A total of 29 cases were followed up for 12 months, and 24 cases (82.8%) had HBV DNA negative conversion. Conclusion:TMF antiviral therapies have an HBV DNA negative rate of over 80% at 12 months and can improve the liver function in patients with hepatitis B cirrhosis. However, there were no significant changes in renal function and blood lipids before and after treatment.
